search
Back to results

Height Versus Height and Weight Based Spinal Bupivacaine on Maternal Haemodynamics for Elective Cesarean in Short Stature Patients

Primary Purpose

Maternal Hypotension After Spinal Anesthesia

Status
Completed
Phase
Phase 4
Locations
Nepal
Study Type
Interventional
Intervention
Hyperbaric bupivacaine spinal
Hyperbaric bupivacaine spinal
Sponsored by
B.P. Koirala Institute of Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Maternal Hypotension After Spinal Anesthesia

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women with full-term gestation undergoing planned Caesarean section under spinal anesthesia
  • Who provide consent .
  • Height less than 150 cm

Exclusion Criteria:

  • Patients with height <140 cm,
  • Hypertensive disorders of pregnancy,
  • Placental disorders,
  • Body mass index ≥ 40 kg/m2,
  • Diabetes mellitus
  • Cardiovascular
  • Cerebrovascular
  • Hormonal disorder
  • Renal disease
  • Polyhydramnios
  • Known case of bad obstetric history
  • Fetal abnormalities
  • Baseline systolic blood pressure (SBP) less than 100 mmHg
  • Contraindication to spinal anaesthesia
  • Allergy to any drug used in the study and
  • Those unable to understand and sign the consent form

Sites / Locations

  • BP Koirala Institute of Health Sciences (BPKIHS)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Height and weight based group

Height based group

Arm Description

Patients in "Height and weight based group" will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)

Patients in "Height based group" will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)

Outcomes

Primary Outcome Measures

Incidence of post-spinal hypotension
Number of patients with post spinal hypotension (defined as systolic blood pressure in mmHg, <10% of the baseline reading or SBP < 100 mm Hg observed from spinal injection until delivery of baby

Secondary Outcome Measures

Incidence of post-delivery hypotension
Number of patients with post delivery hypotension (defined as systolic blood pressure in mmHg, <10% from the baseline reading or systolic blood pressure < 100 mm Hg observed after delivery of the fetus and starting oxytocin infusion until end of surgery
Incidence of post-spinal hypotension
Number of patients with post spinal hypotension (defined as systolic blood pressure in mmHg, <20% of the baseline reading or SBP < 100 mm Hg observed from spinal injection until delivery of baby
Incidence of post-delivery hypotension
Number of patients with post delivery hypotension (defined as systolic blood pressure in mmHg, <20% of the baseline reading or systolic blood pressure < 100 mm Hg observed after delivery of the fetus and starting oxytocin infusion until end of surgery
Lowest systolic blood pressure
lowest systolic blood pressure (SBP) recorded in mmHg from spinal injection until delivery and then end of surgery.
Vasopressor requirement
Hypotension associated without bradycardia will be treated with phenylepinephrine. Hypotension associated with bradycardia (HR 50/min) will be treated with IV ephedrine 6 mg and followed by IV atropine 0.5 mg.
Incidence of bradycardia
Number of patients with heart rate < 50 beats/min
Incidence of nausea vomiting
Number of patients complaining nausea and vomiting. Patients will be instructed to report intraoperative nausea based on an 11-point Numeric Rating Score (NRS), where 0 describes "no nausea" and 10 describes nausea "as worst as it could be". Score more than 0 will be considered as nausea. Patients reporting NRS score > 3 for nausea or vomiting will be managed with IV ondensetron 4 mg. If nausea and vomiting persisted after 5 min, IV dexamethasone 4 mg will be administered.
Incidence of shivering
Number of patients with shivering. Intraoperative shivering will be graded as : 0 no shivering, 1 one or more of the following: piloerection, peripheral vasoconstriction, peripheral cyanosis without other cause, but without visible muscular activity; 2 visible muscular activity confined to one muscle group; 3 visible muscular activity in more than one muscle group; and 4 gross muscular activity involving the whole body. If the shivering score is ≥3, IV meperidine 20 mg will be administered.
Intraoperative analgesia requirement
Number of patient requiring intraoperative supplemental analgesia. Patients will be instructed to report intraoperative pain based on an 11-point Numeric Rating Score (NRS), where 0 describes "no pain" and 10 describes worst pain "as worst as it could be". It will be assessed using NRS scores at the following intervals: skin incision, delivery, uterine exteriorization, peritoneal closure, and skin closure. If patients reported pain or discomfort (if NRS is mild i.e scores between 1-3), then IV fentanyl 20 microgram will be given and second dose will be repeated if needed. If pain still persists then IV ketamine 0.25 mg/kg will be given.
Systolic blood pressure
Systolic blood pressure in mmHg measured from baseline until end of surgery
Quality of anaesthesia
Assessed using a four-point scale: 1=excellent, 2=good; some feelings but no discomfort, 3=fair; some discomfort but rescue analgesia unnecessary, 4=poor; major discomfort and rescue analgesia required.
quality of operating condition
Surgeons will be asked to grade operating conditions as "very good," "good," or "poor."
Intraoperative sedation
Assessed at 5 min interval after IT injection using a 5-point ordinal scale, where 0 = Awake and alert; 1 = resting with eyes closed; 2 = drowsy and responsive to verbal stimuli; 3 = drowsy and responsive to physical stimuli and 4 = unarousable.
Maternal satisfaction with intraoperative anesthesia for cesarean delivery
It will be recorded before discharge from PACU using a NRS with "very dissatisfied" at 0 cm and "very satisfied" at 10 cm.
Incidence of pruritus
Number of patients with pruritus. Intraoperative pruritus will be assessed using NRS scale (0 - 10 scale, with 0, no pruritus, and 10, worst pruritus imaginable). NRS score > 3 will be treated with IV chlorpheniramine 10 mg.
Duration of pain free period
Duration of analgesia in hours (time elapsed between intrathecal injection and the first perception of pain) will be noted
Incidence of dizziness
Number of patients complaining dizziness
Time to sensory block reached to 6th thoracic dermatome
After spinal anesthesia the time required for sensory block to reach 6th thoracic dermatome
Maximum level of sensory block reached
level of maximum thoracic/cervical dermatome reached after spinal anesthesia
Time to sensory block regressed to 10th thoracic dermatome
After spinal anesthesia the time required for sensory block to regress to 10th thoracic dematome
Time to complete motor blockade
Time to Bromage scale 3. Motor block will be assessed using the Bromage scale (0-3): 0, able to straight leg raise (SLR) and flex both feet and knees; 1, unable to SLR, able to flex knees and feet; 2, unable to SLR or flex knees, able to flex feet; and 3, unable to move legs or feet.
Time to motor blockage regression
Time to Bromage scale regression to 0. Motor block will be assessed using the Bromage scale (0-3): 0, able to straight leg raise (SLR) and flex both feet and knees; 1, unable to SLR, able to flex knees and feet; 2, unable to SLR or flex knees, able to flex feet; and 3, unable to move legs or feet.
Apgar score
Neonatal Apgar scores after delivery assessed by attending pediatrician. It is determined by evaluating the newborn baby on five criteria(Appearance, Pulse, Grimace, Activity, Respiration) on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. Scores 7 and above are generally normal; 4 to 6, fairly low; and 3 and below are generally regarded as critically low requiring immediate resuscitation.

Full Information

First Posted
September 1, 2019
Last Updated
March 8, 2022
Sponsor
B.P. Koirala Institute of Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT04082676
Brief Title
Height Versus Height and Weight Based Spinal Bupivacaine on Maternal Haemodynamics for Elective Cesarean in Short Stature Patients
Official Title
Effect of Height Versus Height and Weight Based Intrathecal Bupivacaine Dose on Maternal Haemodynamics for Elective Caesarean Section in Short Stature Patients: A Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 30, 2019 (Actual)
Primary Completion Date
September 1, 2021 (Actual)
Study Completion Date
September 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
B.P. Koirala Institute of Health Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Doses of intrathecal bupivacaine based on patients either height or height and weight has shown to lower the risk of maternal hypotension with similar quality of anesthesia compared to conventional doses. In clinical practice there is a tendency of reducing the dose of bupivacaine as either low fixed dose or using the doses based on either height and weight or height (0.06mg/cm) alone in parturient with short stature. However, there is lack of evidence regarding the appropriate dose required in this group of patients. Therefore, our aim is to compare the height versus height and weight based intrathecal bupivacaine dose for elective caesarean on maternal haemodynamics in short stature patients.
Detailed Description
Spinal induced hypotension in women undergoing caesarean section (CS) is the most common unwanted effect. The dose of intrathecal local anesthetic is the main determining factor that balances between successful block and an incidence of maternal hypotension. Although lowering the doses of intrathecal bupivacaine provides better maternal hemodynamic stability it compromises the quality of anesthesia. Moreover, there is no consensus regarding the cut-off at which the dose can be defined as low. Doses based on patients either height or height and weight has shown to lower the risk of maternal hypotension with similar quality of anesthesia compared to conventional doses. In clinical practice there is a tendency of reducing the dose of bupivacaine as either low fixed dose or using the doses based on either height and weight or height (0.06mg/cm) alone in parturient with short stature. However, there is lack of evidence regarding the appropriate dose required in this group of patients. Our aim is to compare the height versus height and weight based intrathecal bupivacaine dose for elective caesarean on maternal haemodynamics in short stature patients. Doses of intrathecal bupivacaine for elective caesarean section based on Harten chart is available from the following reference- Harten JM, Boyne I, Hannah P, Varveris D, Brown A. Effects of a height and weight adjusted dose of local anaesthetic for spinal anaesthesia for elective Caesarean section. Anaesthesia 2005; 60: 348-53. Consent for the participation in the study will be obtained during pre-anaesthetic assessment visits in the evening before surgery. The investigator will also educate the patients regarding the use of numeric rating scale scores. Preoperative anxiety will be recorded in numerical rating scale scores where 0 is no anxiety and 10 is maximum anxiety patient reported. The enrolled subjects will be randomly assigned to 2 equal groups (allocation ratio, 1:1) according to the codes generated from the website (www.sealedenvleop.com) using the variable block size of 4, 6 and 8. The group allocation will be concealed in sequentially numbered, sealed opaque envelopes that will be opened by the anaesthesia assistant not involved in the study only after the patient arrives in the operating room. The patient will be fasted for at least eight hours and will receive antibiotics, ranitidine 50 mg and metoclopramide 10 mg intravenously via 18-gauge cannula before transfer to the operation room. In the operating table patient will be laid supine with a wedge under right buttock and standard monitors (electrocardiography, pulse oximetry, and noninvasive BP) will be applied. Thereafter, successive three readings of heart rate (HR) and systolic blood pressure (SBP) will be taken at 2 minutes interval with difference not exceeding 10%. The average of these recordings will be documented by the investigators as baseline parameters. To maintain blinding, the investigator will leave the operating room and will return immediately once the spinal injection is initiated. Subarachnoid block will be performed by the attending anesthesiologist not involved in the study in the sitting position at the L3-L4 or L4-L5 vertebral interspace using a 25-gauge spinal needle via midline approach. The study solution will be administered according to the group allocated. In Group A the dose of heavy bupivacaine will be based on height and weight and in group B the dose will be based on patient's height (0.06 mg/cm). 10 microgram fentanyl will be added to bupivacaine in both groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Maternal Hypotension After Spinal Anesthesia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
112 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Height and weight based group
Arm Type
Experimental
Arm Description
Patients in "Height and weight based group" will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
Arm Title
Height based group
Arm Type
Active Comparator
Arm Description
Patients in "Height based group" will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
Intervention Type
Drug
Intervention Name(s)
Hyperbaric bupivacaine spinal
Intervention Description
In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
Intervention Type
Drug
Intervention Name(s)
Hyperbaric bupivacaine spinal
Intervention Description
In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
Primary Outcome Measure Information:
Title
Incidence of post-spinal hypotension
Description
Number of patients with post spinal hypotension (defined as systolic blood pressure in mmHg, <10% of the baseline reading or SBP < 100 mm Hg observed from spinal injection until delivery of baby
Time Frame
Up to delivery of baby
Secondary Outcome Measure Information:
Title
Incidence of post-delivery hypotension
Description
Number of patients with post delivery hypotension (defined as systolic blood pressure in mmHg, <10% from the baseline reading or systolic blood pressure < 100 mm Hg observed after delivery of the fetus and starting oxytocin infusion until end of surgery
Time Frame
Up to end of surgery
Title
Incidence of post-spinal hypotension
Description
Number of patients with post spinal hypotension (defined as systolic blood pressure in mmHg, <20% of the baseline reading or SBP < 100 mm Hg observed from spinal injection until delivery of baby
Time Frame
Up to delivery of baby
Title
Incidence of post-delivery hypotension
Description
Number of patients with post delivery hypotension (defined as systolic blood pressure in mmHg, <20% of the baseline reading or systolic blood pressure < 100 mm Hg observed after delivery of the fetus and starting oxytocin infusion until end of surgery
Time Frame
Up to end of surgery
Title
Lowest systolic blood pressure
Description
lowest systolic blood pressure (SBP) recorded in mmHg from spinal injection until delivery and then end of surgery.
Time Frame
Up to end of surgery
Title
Vasopressor requirement
Description
Hypotension associated without bradycardia will be treated with phenylepinephrine. Hypotension associated with bradycardia (HR 50/min) will be treated with IV ephedrine 6 mg and followed by IV atropine 0.5 mg.
Time Frame
Up to end of surgery
Title
Incidence of bradycardia
Description
Number of patients with heart rate < 50 beats/min
Time Frame
Up to end of surgery
Title
Incidence of nausea vomiting
Description
Number of patients complaining nausea and vomiting. Patients will be instructed to report intraoperative nausea based on an 11-point Numeric Rating Score (NRS), where 0 describes "no nausea" and 10 describes nausea "as worst as it could be". Score more than 0 will be considered as nausea. Patients reporting NRS score > 3 for nausea or vomiting will be managed with IV ondensetron 4 mg. If nausea and vomiting persisted after 5 min, IV dexamethasone 4 mg will be administered.
Time Frame
Up to end of surgery
Title
Incidence of shivering
Description
Number of patients with shivering. Intraoperative shivering will be graded as : 0 no shivering, 1 one or more of the following: piloerection, peripheral vasoconstriction, peripheral cyanosis without other cause, but without visible muscular activity; 2 visible muscular activity confined to one muscle group; 3 visible muscular activity in more than one muscle group; and 4 gross muscular activity involving the whole body. If the shivering score is ≥3, IV meperidine 20 mg will be administered.
Time Frame
Up to end of surgery
Title
Intraoperative analgesia requirement
Description
Number of patient requiring intraoperative supplemental analgesia. Patients will be instructed to report intraoperative pain based on an 11-point Numeric Rating Score (NRS), where 0 describes "no pain" and 10 describes worst pain "as worst as it could be". It will be assessed using NRS scores at the following intervals: skin incision, delivery, uterine exteriorization, peritoneal closure, and skin closure. If patients reported pain or discomfort (if NRS is mild i.e scores between 1-3), then IV fentanyl 20 microgram will be given and second dose will be repeated if needed. If pain still persists then IV ketamine 0.25 mg/kg will be given.
Time Frame
Up to end of surgery
Title
Systolic blood pressure
Description
Systolic blood pressure in mmHg measured from baseline until end of surgery
Time Frame
Up to end of surgery
Title
Quality of anaesthesia
Description
Assessed using a four-point scale: 1=excellent, 2=good; some feelings but no discomfort, 3=fair; some discomfort but rescue analgesia unnecessary, 4=poor; major discomfort and rescue analgesia required.
Time Frame
At 1 to 2 hours in Post anesthesia care unit
Title
quality of operating condition
Description
Surgeons will be asked to grade operating conditions as "very good," "good," or "poor."
Time Frame
Up to end of surgery
Title
Intraoperative sedation
Description
Assessed at 5 min interval after IT injection using a 5-point ordinal scale, where 0 = Awake and alert; 1 = resting with eyes closed; 2 = drowsy and responsive to verbal stimuli; 3 = drowsy and responsive to physical stimuli and 4 = unarousable.
Time Frame
Up to end of surgery
Title
Maternal satisfaction with intraoperative anesthesia for cesarean delivery
Description
It will be recorded before discharge from PACU using a NRS with "very dissatisfied" at 0 cm and "very satisfied" at 10 cm.
Time Frame
up to 1-2 hours stay Post anesthesia care unit
Title
Incidence of pruritus
Description
Number of patients with pruritus. Intraoperative pruritus will be assessed using NRS scale (0 - 10 scale, with 0, no pruritus, and 10, worst pruritus imaginable). NRS score > 3 will be treated with IV chlorpheniramine 10 mg.
Time Frame
Up to end of surgery
Title
Duration of pain free period
Description
Duration of analgesia in hours (time elapsed between intrathecal injection and the first perception of pain) will be noted
Time Frame
up to 24 h after surgery
Title
Incidence of dizziness
Description
Number of patients complaining dizziness
Time Frame
up to end of surgery
Title
Time to sensory block reached to 6th thoracic dermatome
Description
After spinal anesthesia the time required for sensory block to reach 6th thoracic dermatome
Time Frame
Up to 10 min from injection of spinal anesthesia
Title
Maximum level of sensory block reached
Description
level of maximum thoracic/cervical dermatome reached after spinal anesthesia
Time Frame
Up to end of surgery
Title
Time to sensory block regressed to 10th thoracic dermatome
Description
After spinal anesthesia the time required for sensory block to regress to 10th thoracic dematome
Time Frame
Up to 24 hour after surgery
Title
Time to complete motor blockade
Description
Time to Bromage scale 3. Motor block will be assessed using the Bromage scale (0-3): 0, able to straight leg raise (SLR) and flex both feet and knees; 1, unable to SLR, able to flex knees and feet; 2, unable to SLR or flex knees, able to flex feet; and 3, unable to move legs or feet.
Time Frame
Upto 15 min after spinal anesthesia
Title
Time to motor blockage regression
Description
Time to Bromage scale regression to 0. Motor block will be assessed using the Bromage scale (0-3): 0, able to straight leg raise (SLR) and flex both feet and knees; 1, unable to SLR, able to flex knees and feet; 2, unable to SLR or flex knees, able to flex feet; and 3, unable to move legs or feet.
Time Frame
Up to 24 hour after surgery
Title
Apgar score
Description
Neonatal Apgar scores after delivery assessed by attending pediatrician. It is determined by evaluating the newborn baby on five criteria(Appearance, Pulse, Grimace, Activity, Respiration) on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. Scores 7 and above are generally normal; 4 to 6, fairly low; and 3 and below are generally regarded as critically low requiring immediate resuscitation.
Time Frame
5 and 10 minutes after delivery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women with full-term gestation undergoing planned Caesarean section under spinal anesthesia Who provide consent . Height less than 150 cm Exclusion Criteria: Patients with height <140 cm, Hypertensive disorders of pregnancy, Placental disorders, Body mass index ≥ 40 kg/m2, Diabetes mellitus Cardiovascular Cerebrovascular Hormonal disorder Renal disease Polyhydramnios Known case of bad obstetric history Fetal abnormalities Baseline systolic blood pressure (SBP) less than 100 mmHg Contraindication to spinal anaesthesia Allergy to any drug used in the study and Those unable to understand and sign the consent form
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Asish Subedi, MD
Organizational Affiliation
BP Koirala Institute of Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
BP Koirala Institute of Health Sciences (BPKIHS)
City
Dharān Bāzār
State/Province
Koshi
ZIP/Postal Code
56700
Country
Nepal

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The final research data will be stored in Mendeley. The final data will be released and shared during the publication process of the manuscript.
IPD Sharing Time Frame
The final research data and study protocol will be shared with the journal accepting the article for publication. It will be available simultaneously after publication of the article.
IPD Sharing Access Criteria
The IPD link will be accessed from the link provided in the published manuscript. The IPD may also be available to other researchers by the investigators upon request.
IPD Sharing URL
https://data.mendeley.com/

Learn more about this trial

Height Versus Height and Weight Based Spinal Bupivacaine on Maternal Haemodynamics for Elective Cesarean in Short Stature Patients

We'll reach out to this number within 24 hrs